Immunotherapy for Lung Cancer

On June 24, 2014, Glenn Dranoff, MD, a professor of medicine at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, discussed how recent research has begun to clarify the ways in which lung cancer cells escape from the immune system. This knowledge in turn has led to the crafting of new forms of immunotherapy aimed at overcoming these escape pathways. Clinical trials indicate that these new types of immunotherapies can help destroy and control some lung cancers in patients. These exciting results pave the way for developing even more potent immunotherapies for lung cancer.

Dr. Dranoff is also an associate director of the Cancer Research Institute Scientific Advisory Council and a member of the Academy of Cancer Immunology, the American Society of Clinical Investigation, the European Academy of Tumor Immunology, and the Osler Interurban Clinical Club. Dr. Dranoff received his B.S. from Duke University and his MD from Duke University School of Medicine. He completed an internship and residency in internal medicine at Massachusetts General Hospital and a clinical fellowship in medical oncology at DFCI. He received postdoctoral training at the Whitehead Institute. His research focuses on understanding the molecular and cellular mechanisms underlying the stimulation of antitumor immunity, and on the development of cancer vaccines.

This webinar is part of the Cancer Research Institute's webinar series, "Cancer Immunotherapy and You," which are offered free to the public and feature informative updates for patients and caregivers from leaders in cancer immunotherapy, followed by a Q&A. This webinar was generously supported by Agenus. For more information on this webinar, or to register for upcoming webinars, please visit www.cancerresearch.org/webinars.